Safety and Efficacy of Allogeneic HPV-specific T Cells in Adults With Recurrent or Metastatic HPV16+ Cancers

NCT ID: NCT04713046

Last Updated: 2025-10-24

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-10-18
• Study Completion Date: 2026-10-01

Brief Summary

In this study, haploidentical relatives of a patient with recurrent or metastatic HPV 16-associated malignancy will be vaccinated with a therapeutic human papillomavirus (HPV) vaccine series to generate HPV-specific leukocytes. The cancer patient with recurrent or metastatic HPV16+ cancer will then be randomized to one of two arms: 1) non-myeloablative allogeneic bone marrow transplant or 2) cluster of differentiation 8 (CD8)-depleted donor lymphocyte infusion.

Conditions

HPV 16+ Recurrent or Metastatic Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Allogeneic bone marrow transplant

non-myeloablative allogeneic bone marrow transplant (BMT) from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.

Group Type: EXPERIMENTAL

Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16

Intervention Type: BIOLOGICAL

Standard dosing for bone marrow graft (target dose of 4 x 10\^8 nucleated cells/kg) and if progression at Day 90, will receive dose level 1 for the CD8-depleted DLI (106 CD4+ cell/kg).

CD8-depleted donor lymphocyte infusion (DLI) per dose escalation scheme

CD8-depleted donor lymphocyte infusion per dose escalation scheme from a haploidentical relative after vaccination with a therapeutic HPV vaccine series.

Group Type: EXPERIMENTAL

CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16

Intervention Type: BIOLOGICAL

Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10\^6 CD4+ cells/kg; 2) 5 x 10\^6 CD4+ cells/kg; or 3) 10\^7 CD4+ cells/kg of recipient ideal body weight.

Interventions

CD8 reduced peripheral blood cells taken from related donors vaccinated against HPV16

Patients will receive CD8+ T cell-depleted peripheral blood cells at one of three dose levels following cyclophosphamide: 1) 10\^6 CD4+ cells/kg; 2) 5 x 10\^6 CD4+ cells/kg; or 3) 10\^7 CD4+ cells/kg of recipient ideal body weight.

Intervention Type: BIOLOGICAL

Non-myeloablative allogeneic bone marrow transplant from related donors vaccinated against HPV16

Standard dosing for bone marrow graft (target dose of 4 x 10\^8 nucleated cells/kg) and if progression at Day 90, will receive dose level 1 for the CD8-depleted DLI (106 CD4+ cell/kg).

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

1. Have pathologically confirmed incurable, locally recurrent or metastatic HPV16+ HNSCC

2. Male or female ≥ 18 years of age

3. Have an human leukocyte antigen (HLA) partially mismatched (haploidentical) related donor. Acceptable donors include first degree relatives (parent, child, or haploidentical sibling), half-siblings, or second degree relatives (aunt, uncle, cousin, niece, nephew). A patient who has inherited a recombinant haplotype from the parents is eligible if the donor shares at least 1 HLA antigen at each of the HLA-A, HLA-B, and HLA DR isotype (HLA-DR) loci.

4. Prior treatment with a platinum-containing regimen

5. Patients with an FDA-approved indication to receive an anti-programmed cell death protein-1 (PD-1) or anti-programmed death-ligand1 (PD-L1) monoclonal antibody must have received at least one cycle of this therapy prior to receiving treatment on this trial

6. Life expectancy ≥ 4 months at time of screening

7. Measurable disease using RECIST 1.1. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been documented in such lesions

8. Eastern Cooperative Oncology Group (ECOG) performance status of < 2 (see Appendix A).

9. Adequate organ function per the protocol, as defined below:

• Left ventricular ejection fraction > 35% (within 30 days of eligibility screening)
• Total bilirubin < 3.0 mg/dl unless from Gilbert disease
• aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 4 x institutional upper limit of normal
• Serum creatinine < 3.0 mg/dl

10. Willing and able to provide written informed consent

Exclusion Criteria

1. Disease that is suitable for local therapy administered with curative intent

2. Requires vasopressor or ventilator support

3. Received antithymocyte globulin or similar anti-T-cell antibody therapy ≤ 4 weeks prior to Cycle 1 Day 1

4. Diagnosis of immunodeficiency or is receiving systemic steroid therapy >10 mg/day of prednisone or equivalent, or any other form of immunosuppressive therapy within 7 days prior to Cycle 1 Day 1 of study treatment.

5. Active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.

6. Active infection requiring systemic therapy

7. History of (non-infectious) pneumonitis that required steroids or current pneumonitis

8. Received any live vaccine for up to 30 days prior to enrollment.

9. Known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer not associated with HPV16.

10. Pregnancy or breastfeeding: females of childbearing potential must have a negative serum pregnancy test.

11. Female of childbearing potential or male with a female partner of childbearing potential unwilling to use a highly effective method of contraception (abstinence is acceptable) for the course of the study through 120 days after the last study dose since the effects of this therapy on the developing human fetus are unknown.

12. Inability to comply with study procedures

13. Received chemotherapy or targeted small molecule therapy within 2 weeks of the first dose of cyclophosphamide. Subjects must have recovered (ie, grade ≤ 1 or at baseline) from adverse events (AEs) due to a previously administered agent. Subjects with grade ≤ 2 neuropathy or grade ≤ 2 alopecia are an exception to this criterion.

14. Received prior radiotherapy within 2 weeks of the first dose of cyclophosphamide. Subjects must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis. A 1- week washout is permitted for palliative radiation (≤ 2 weeks of radiotherapy) to non-central nervous system (CNS) disease.

15. Carcinomatous meningitis; and/or active CNS metastases, unless metastases are treated and stable and the subject does not require systemic steroids.

16. Known history of human immunodeficiency virus (HIV), known active hepatitis B virus (HBV; e.g., hepatitis B surface antigen [HBsAg] reactive), or hepatitis C virus (HCV; e.g., HCV ribonucleic acid [RNA] is detected)

17. Prior treatment with HPV T cells

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

PapiVax Biotech, Inc.

OTHER

Sponsor Role: collaborator

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tanguy Seiwert, MD

Role: PRINCIPAL_INVESTIGATOR

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Locations

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Baltimore, Maryland, United States

Site Status: RECRUITING

Countries

United States

Central Contacts

Tanguy Seiwert, MD

Role: CONTACT

tseiwert@jhmi.edu

410-955-8893

Adrienne Holmes, RN

Role: CONTACT

aholme26@jhmi.edu

410-955-9927

Facility Contacts

Tanguy Seiwert, MD

Role: primary

tseiwert@jhmi.edu

410-955-8893

Adrienne Holmes, RN

Role: backup

aholme26@jhmi.edu

410-955-9927

Other Identifiers

IRB00244082

Identifier Type: OTHER

Identifier Source: secondary_id

J21112

Identifier Type: -

Identifier Source: org_study_id